Aripiprazole orally disintegrating tablets treat schizophrenia. The drug is a partial agonist at D2 receptors and 5-HT1A receptors and an antagonist at 5-HT2A receptors. Its production is mediated by agonism of D2 receptors and 5-HT1A receptors, and antagonism of 5-HT2A receptors. Therefore, the drug is clinically used in the treatment of schizophrenia. There are adverse reactions such as dizziness, headache, nausea and constipation during the use of the drug. It is contraindicated in patients who are allergic to the drug. Patients should be closely monitored during drug therapy, and in order to minimize the risk of overdose, the dose of its use should be kept to a minimum; it should be used with caution in patients at risk of aspiration pneumonia, cardiovascular disease, cerebrovascular disease. If you need to use the drug, it should be used under the guidance of a specialist, not self-medication to avoid adverse reactions.